R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment
With the availability of more data sources and a large variety of applications across a product lifecycle, interest in real-world evidence (RWE) has exploded over the past decade and, given the breadth of its use cases , RWE is sometimes considered as a valuable tool in the health technology assessment (HTA) process. However, barriers to the widespread adoption and acceptance of RWE by HTA agencies still remain.
In the first instalment of this bi-monthly series, Sreeram Ramagopalan, together with Alex Simpson (both F. Hoffmann-La Roche, Basel, Switzerland), highlight developments in both RWE as it relates to HTA and acceptance of RWE by HTA agencies, discussing news of interest for each.View the full article